**Core Concept:** Neonatal hearing screening is a critical evaluation performed on newborn infants to detect any hearing impairment at an early stage, allowing for timely intervention and rehabilitation. This can prevent speech and language development delays. Several tests are available for this purpose, including auditory brainstem response (ABR), otoacoustic emissions (OAE), and transient evoked otoacoustic emissions (TEOAE).

**Why the Correct Answer is Right:** Auditory brainstem response (ABR) is the preferred neonatal screening test for hearing as it can detect both conductive and sensorineural hearing loss. ABR measures the electrical response of the auditory pathway from the cochlea to the brainstem in response to auditory stimuli. This test can identify hearing problems at various levels of the auditory pathway, making it more comprehensive than other tests.

**Why Each Wrong Option is Incorrect:**

A. Otoacoustic emissions (OAE) primarily detects cochlear dysfunction and is less sensitive in detecting more peripheral hearing loss. OAE cannot identify the auditory pathway dysfunction.

B. Transient evoked otoacoustic emissions (TEOAE) assesses the outer hair cells of the cochlea and is less sensitive in detecting more central hearing loss. TEOAE may miss cases of syndromic hearing loss.

C. Pure tone audiometry (PTA) is a diagnostic test performed on older children and adults to determine hearing thresholds at various sound frequencies. It is not suitable for neonatal screening due to its invasiveness, time-consuming nature, and the need for patient cooperation, which may not be feasible in neonates.

**Clinical Pearl:** Early detection of hearing impairment through ABR testing is crucial for timely intervention and rehabilitation, improving the long-term outcomes in children with hearing loss.

**Correct Answer:** Auditory brainstem response (ABR)